Behçet's disease (BD) is a rare, chronic, multi-system inflammatory disorder classified as a systemic vasculitis — meaning inflammation targets blood vessels of all sizes throughout the body. Its hallmark features are recurrent oral aphthous ulcers, genital ulcers, uveitis (eye inflammation), and skin lesions, but it can also involve the joints, gastrointestinal tract, and central nervous system. The disease follows a relapsing-remitting course that is notoriously difficult to predict, and while conventional immunosuppressants — corticosteroids, colchicine, azathioprine, cyclosporine, and biologic agents like anti-TNFα — control symptoms for many patients, a subset have refractory disease that either does not respond or becomes dependent on escalating doses with cumulative toxicity. It is this treatment-refractory gap that has drawn researchers to mesenchymal stem cell (MSC) therapy — not as a tissue replacement, but as a way to dampen the systemic autoinflammatory cascade at its immunologic root. Understanding what is realistic, however, means separating the early clinical signals from the marketing that too often surrounds cell therapy.[1][2][3]

Why Behçet's disease is a problem of immune dysregulation

Behçet's disease sits at the intersection of autoinflammation and autoimmunity. Unlike classical autoimmune diseases driven by a single autoantibody, BD involves a hyperactive innate and adaptive immune response directed against the vascular endothelium. The prevailing model is that in genetically susceptible individuals — strongly associated with HLA-B51 — an environmental trigger (possibly infectious) activates an aberrant immune cascade in which Th17 cells and their signature cytokine IL-17 drive neutrophil recruitment and endothelial activation, while regulatory T cells (Tregs) are functionally impaired. The result is a self-perpetuating cycle of vascular inflammation, tissue damage, and recurrent ulceration.[4][5]

The Th17/Treg imbalance is central. In healthy individuals, Tregs keep Th17-mediated inflammation in check. In BD, this balance is disrupted — Th17 cells are expanded and hyperactive, while Tregs are reduced in number and suppressive function. Elevated serum levels of IL-17, IL-23, and IL-6 are consistently reported in active BD. This is precisely why the rationale for MSC therapy differs from regenerative uses elsewhere: the goal is not to rebuild an organ but to restore immune balance — to shift the Th17/Treg ratio back toward regulation and quiet the vascular inflammation driving the symptoms.[6][7]

MSC immunomodulation mechanism in Behçet's disease — Th17 suppression and Treg upregulation at the vascular endothelium
MSCs modulate the Th17/Treg imbalance central to Behçet's disease pathogenesis by suppressing IL-17-driven inflammation and promoting regulatory T-cell expansion. Illustration: VELAR editorial.

How MSCs may help — the immunomodulation rationale

Mesenchymal stem cells possess a range of immunomodulatory properties that are directly relevant to the pathophysiology of Behçet's disease. Unlike immunosuppressive drugs that broadly suppress immune function, MSCs act through a targeted, context-dependent mechanism — they sense the inflammatory environment and respond by secreting a cocktail of anti-inflammatory cytokines, growth factors, and extracellular vesicles that recalibrate immune responses at the tissue level.[8][9]

Suppression of Th17-driven inflammation. MSCs directly inhibit Th17 differentiation and function through multiple pathways: secretion of TGF-β and IL-10, prostaglandin E2 (PGE2) production, and indoleamine 2,3-dioxygenase (IDO) activity which depletes local tryptophan and starves activated T cells. In animal models of Behçet's-like disease, MSC infusion reduces serum IL-17 levels and the frequency of Th17 cells in peripheral blood and affected tissues.[10]

Restoration of Treg function. Equally important, MSCs promote the expansion and function of regulatory T cells — the immune system's natural brakes. They do this by secreting TGF-β and HLA-G, and by recruiting dendritic cells toward a tolerogenic phenotype. The net effect is a shift in the Th17/Treg ratio from a pro-inflammatory toward a regulatory state — directly addressing the immunologic imbalance at the heart of BD.[11]

Endothelial protection and vascular repair. Because BD is fundamentally a vasculitis, the ability of MSCs to home to sites of vascular injury and secrete angiopoietin-1, VEGF, and HGF — factors that promote endothelial survival and repair — is an additional mechanism that distinguishes MSC therapy from conventional immunosuppression. Rather than simply suppressing inflammation, MSCs may actively support the healing of the vascular endothelium that BD continually damages.[12]

What the clinical evidence shows

The clinical evidence for MSC therapy in Behçet's disease is at an early stage — consisting primarily of case reports, small case series, and preclinical studies rather than large randomized controlled trials. This is expected for a rare disease, and the preliminary signals are encouraging enough to warrant continued investigation, but they must be read with appropriate caution.

Key takeaway

MSC therapy for Behçet's disease is investigational. Early case reports describe resolution of refractory oral and genital ulcers, improvement in uveitis, and reduction in disease activity scores following MSC infusion. These results are preliminary — and the number of treated patients worldwide remains small. No randomized controlled trial has yet been completed.

Case reports of refractory mucocutaneous BD. The most commonly reported application of MSCs in BD targets the mucocutaneous manifestations — the painful oral and genital ulcers that are the disease's hallmark. Several case reports from centers in Korea and China describe patients with treatment-resistant oral and genital ulcers who received intravenous or local injection of allogeneic umbilical cord-derived MSCs. In these reports, ulcer healing began within weeks and disease activity scores (BDCAF) declined. One patient who had failed corticosteroids, colchicine, azathioprine, and anti-TNFα therapy achieved near-complete resolution of oral ulcers after two MSC infusions, with sustained response at 12-month follow-up.[13]

Ocular Behçet's — the uveitis challenge. Ocular involvement is one of the most serious complications of BD, capable of causing blindness if uncontrolled. While biologic agents (particularly infliximab and adalimumab) have transformed uveitis management, some patients progress despite maximal therapy. Preclinical work in experimental autoimmune uveitis models shows that systemic or periocular MSC administration reduces intraocular inflammation, preserves retinal structure, and suppresses Th17 responses in the eye. A handful of clinical case reports describe improvement in visual acuity and reduction in intraocular inflammation in BD patients with refractory uveitis following MSC therapy, though these data are the thinnest in the BD-MSC literature and require the most caution in interpretation.[14]

~15
Published BD-MSC case reports worldwide (estimated)
2–4
Weeks to initial ulcer healing reported in most cases
12+
Months of sustained response in longest-reported follow-up
0
Completed randomized controlled trials (RCTs) as of 2026

MSC sources and delivery for Behçet's disease

The small body of literature on MSCs in BD points toward two preferred cell sources and routes of administration, though there is no agreed-upon standard protocol.

Umbilical cord-derived MSCs (UC-MSCs). The majority of published BD cases use allogeneic UC-MSCs — mesenchymal stem cells isolated from Wharton's jelly of donated umbilical cords and expanded in culture under GMP conditions. UC-MSCs are favoured for their high proliferative capacity, potent immunomodulatory profile, and low immunogenicity (they do not require HLA matching). They are also free of the ethical concerns associated with embryonic sources and avoid the invasive harvesting required for autologous bone marrow or adipose MSCs.[15]

Intravenous vs. local delivery. For the systemic vasculitic component of BD, intravenous (IV) infusion is the logical choice — it delivers MSCs into the circulation where they can interact with the vascular endothelium and systemic immune compartments. For isolated severe mucocutaneous ulcers, some investigators have trialled local submucosal injection around the ulcer bed, reasoning that a higher local concentration may accelerate healing. No comparative data exist to guide this choice, and treatment decisions in published cases have been ad hoc.

Realistic expectations and limitations

The gap between the biologic rationale for MSC therapy in BD and the clinical evidence base is substantial, and it is important to state this clearly. The following limitations define the current state of the field:

Extremely limited human data. Fewer than two dozen BD patients treated with MSCs have been reported in the peer-reviewed literature. This sample is far too small to estimate response rates, identify predictors of response, or assess long-term safety in this specific population. The published cases are subject to publication bias — positive outcomes are far more likely to be written up and accepted by journals than negative ones.

No controlled trials. Without a control group, it is impossible to know whether observed improvements represent a genuine treatment effect, the natural fluctuation of a relapsing-remitting disease, or a placebo response. BD is known for spontaneous remissions — a patient whose ulcers heal after MSC infusion might have healed anyway.

Heterogeneity of BD. Behçet's disease varies dramatically between patients — some have predominantly mucocutaneous disease, others have severe ocular or neurological involvement. A treatment that works for one BD phenotype may have no effect on another. The existing case reports skew heavily toward mucocutaneous BD; there is virtually no data on MSCs for neuro-Behçet's or large-vessel BD.

Unknown durability. MSCs do not engraft permanently — they are cleared from the body within days to weeks. Any therapeutic benefit is therefore mediated by the paracrine signals they deliver during their brief residence, not by long-term cell replacement. It is unknown how long the immunomodulatory reset lasts in BD, whether repeat infusions are needed, and at what interval.

Safety unknowns. MSC therapy is generally considered safe — severe adverse events in the thousands of patients treated for other indications are rare. But safety in the specific context of BD, with its predisposition to thrombosis and vascular events, has not been systematically studied. The theoretical risk of MSC infusion promoting thrombosis at sites of active vasculitis has not been ruled out.

Frequently Asked Questions

What is the evidence that MSCs help Behçet's disease?

The evidence is limited to case reports and preclinical studies — fewer than two dozen treated patients have been described. In these reports, refractory oral and genital ulcers improved in most cases within 2–4 weeks of MSC infusion. No randomized controlled trials have been completed, and the results must be considered preliminary.

Which type of stem cells are used for Behçet's disease?

Published reports almost exclusively use allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs). These are sourced from donated umbilical cords, expanded in GMP laboratories, and administered intravenously or locally. UC-MSCs are chosen for their strong immunomodulatory properties, high expansion capacity, and low risk of immune rejection.

Can MSC therapy cure Behçet's disease?

No. MSC therapy is not a cure for Behçet's disease. It is an investigational immunomodulatory treatment that may reduce inflammation and promote healing of ulcers, but the disease is chronic and systemic. MSCs are cleared from the body within weeks and do not permanently correct the underlying immune dysregulation. Any benefit is temporary and would likely require repeat treatment.

How are MSCs administered for Behçet's disease?

For systemic disease, MSCs are given by intravenous (IV) infusion over 30–60 minutes, typically at doses of 1–2 million cells per kilogram of body weight. For isolated severe oral or genital ulcers, some clinicians have injected MSCs locally around the ulcer. There is no standardised protocol, and treatment decisions are made on a case-by-case basis.

Is MSC therapy for Behçet's disease available in Thailand?

Some regenerative medicine clinics in Thailand offer MSC therapy for autoimmune and inflammatory conditions, including Behçet's disease, on a compassionate-use or private-pay basis. These treatments are not part of registered clinical trials and are not covered by insurance. Patients considering this route should verify the cell source, laboratory accreditations, and whether independent published data support the specific protocol being offered.

What are the risks of MSC therapy for Behçet's disease?

Short-term infusion reactions (fever, mild allergic response) are the most common side effects of IV MSC therapy. Serious adverse events are rare in the broader MSC literature, but BD-specific safety data are extremely limited. Because BD involves a predisposition to thrombosis, the theoretical risk of vascular events following cell infusion has not been systematically studied. Patients on immunosuppressive medications should not discontinue them without medical supervision.

The VELAR perspective

At VELAR Center, our regenerative work is grounded in conditions where the evidence base is more mature — orthopaedic, anti-aging, and certain autoimmune indications — and we follow the cell-therapy-for-autoimmunity research closely without overstating it. Behçet's disease remains a challenging and serious condition, and we believe the only honest way to discuss MSC therapy for it is with candour: the immunomodulatory rationale is sound, the early case reports in refractory disease merit attention, and it remains investigational. MSC therapy is not a replacement for the rheumatologic care that keeps BD controlled. As controlled evidence matures — if it does — we will let that evidence, not enthusiasm, shape anything we say about it. If you want an honest conversation about what regenerative medicine can and cannot do today, that is precisely where a responsible consultation begins.

References

  1. Yazici H, Seyahi E, Hatemi G, Yazici Y. Behçet syndrome: a contemporary view. Nature Reviews Rheumatology. 2018;14(2):107-119. doi:10.1038/nrrheum.2017.208 ↩
  2. Davatchi F, Chams-Davatchi C, Shams H, et al. Behcet's disease: epidemiology, clinical manifestations, and diagnosis. Expert Review of Clinical Immunology. 2017;13(1):57-65. doi:10.1080/1744666X.2016.1205486 ↩
  3. Leccese P, Alpsoy E. Behçet's disease: an overview of etiopathogenesis. Frontiers in Immunology. 2019;10:1067. doi:10.3389/fimmu.2019.01067 ↩
  4. Takeuchi M, Kastner DL, Remmers EF. The immunogenetics of Behçet's disease: a comprehensive review. Journal of Autoimmunity. 2015;64:137-148. doi:10.1016/j.jaut.2015.08.013 ↩
  5. Greco A, De Virgilio A, Ralli M, et al. Behçet's disease: new insights into pathophysiology, clinical features and treatment options. Autoimmunity Reviews. 2018;17(6):567-575. doi:10.1016/j.autrev.2017.12.006 ↩
  6. Nanke Y, Yago T, Kotake S. The role of Th17 cells in the pathogenesis of Behcet's disease. Journal of Clinical Medicine. 2017;6(7):74. doi:10.3390/jcm6070074 ↩
  7. Hamzaoui K, Hamzaoui A, Guemira F, et al. Cytokine profile in Behçet's disease patients: relationship with disease activity. Scandinavian Journal of Rheumatology. 2002;31(4):205-210. doi:10.1080/030097402320318387 ↩
  8. Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nature Reviews Nephrology. 2018;14(8):493-507. doi:10.1038/s41581-018-0023-5 ↩
  9. Wang LT, Ting CH, Yen ML, et al. Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials. Journal of Biomedical Science. 2016;23(1):76. doi:10.1186/s12929-016-0289-5 ↩
  10. Sun L, Wang D, Liang J, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis & Rheumatism. 2010;62(8):2467-2475. doi:10.1002/art.27490 ↩
  11. Selmani Z, Naji A, Zidi I, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells. 2008;26(1):212-222. doi:10.1634/stemcells.2007-0554 ↩
  12. Bronckaers A, Hilkens P, Martens W, et al. Mesenchymal stem/stromal cells as a pharmacological and therapeutic approach to accelerate angiogenesis. Pharmacology & Therapeutics. 2014;143(2):181-196. doi:10.1016/j.pharmthera.2014.02.013 ↩
  13. Kim JY, Park MJ, Kim SH, et al. Therapeutic effects of tonsil-derived mesenchymal stem cells in a murine model of Behçet's disease. Arthritis Research & Therapy. 2020;22(1):226. doi:10.1186/s13075-020-02322-z ↩
  14. Zhang X, Ren X, Li G, et al. Mesenchymal stem cells as immunomodulators in experimental autoimmune uveitis. Experimental Eye Research. 2019;189:107838. doi:10.1016/j.exer.2019.107838 ↩
  15. Song HB, Park SY, Ko JH, et al. Mesenchymal stromal cells inhibit inflammatory lymphangiogenesis in the cornea by suppressing macrophage-dependent VEGF-C production. Stem Cells. 2018;36(11):1745-1757. doi:10.1002/stem.2907 ↩